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Background. Hereditary spastic paraplegia (HSP) is a heterogeneous group of inherited disorders affecting predominantly the
motor cortex and pyramidal tract, which results in slowly progressing gait disorders, as well as spasticity and weakness of lower
extremities. Repetitive transcranial magnetic stimulation (rTMS) has been previously investigated as a therapeutic tool for
similar motor deficits in a number of neurologic conditions. The aim of this randomized, controlled trial was to investigate the
therapeutic potential of rTMS in various forms of HSP, including pure and complicated forms, as well as
adrenomyeloneuropathy. Methods. We recruited 15 patients (five women and 10 men; mean age 43 7 ± 10 6 years) with the
mentioned forms of HSP. The intervention included five sessions of bilateral 10 Hz rTMS over primary motor areas of the
muscles of lower extremities and five sessions of similar sham stimulation. Results. One patient dropped out due to seizure, and
14 patients completed the study protocol. After real stimulation, the strength of the proximal and distal muscles of lower
extremities increased, and the spasticity of the proximal muscles decreased. Change in spasticity was still present during follow-
up assessment. No effect was observed regarding gait velocity. No changes were seen after sham stimulation. A post hoc analysis
revealed an inverse relation between motor threshold and the change of the strength after active rTMS. Conclusions. rTMS may
have potential in improving weakness and spasticity of lower extremities in HSP, especially of proximal muscles whose motor
areas are located more superficially. This trial is registered with Clinicaltrials.gov NCT03627416.
1. Introduction
Hereditary spastic paraplegia (HSP) is a group of genetic
disorders with slowly progressing degeneration of spinal
motor pathways to lower extremities as a predominant
pathologic feature. The key symptoms include impaired
walking, muscle weakness, spasticity, hyperreflexia, and
pyramidal signs as well as hypertonic bladder. Some
genetic mutations associated with HSP predispose to addi-
tional neurologic deficits, such as cerebellar dysfunction,
cognitive impairment, peripheral neuropathy, and extrapy-
ramidal features, which determine the clinical differentia-
tion between pure and complicated forms [1]. Due to a
variety of genetic defects, pathophysiologic mechanisms
in HSP may involve mitochondrial dysfunction, distur-
bances of lipid metabolism, axonal transport, myelination
abnormalities, and a number of other mechanisms, which
all result in the axonopathy of the corticospinal tract,
which primarily affects the longest axons [2].
Adrenomyeloneuropathy (AMN) is another condition,
which is phenotypically very similar to HSP and results from
genetically caused impairment of peroxisomal β-oxidation of
saturated straight-chain very long-chain fatty acids (VLCFA)
[3]. AMN is commonly recognized as the form of adrenoleu-
kodystrophy, a group of phenotypically different disorders
caused by mutation in the ABCD1 gene. Parallelly, other
researchers classify AMN as the x-linked, metabolic form of
HSP [4, 5]. Similarly to HSP, biochemical impairment in
AMN results in the axonal degeneration of the corticospinal
tract with the longest axons being affected more severely and
spastic paraparesis being the core symptom. In a subset of
patients, peripheral neuropathy and cerebral demyelination
may develop [6]. Currently, no disease-modifying therapy
for any type of spastic paraparesis mentioned is available.
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Progressive weakness, spasticity, and walking impairment
lead in many cases to wheelchair dependency and profoundly
affect the quality of life [7].
Repetitive transcranial magnetic stimulation (rTMS) is a
method of noninvasive modulation of brain activity, increas-
ingly used in various psychiatric and neurologic conditions.
Therapeutic benefits are related to induction of brain plastic-
ity in disease-specific cortical areas, which is mediated by
trains of magnetic pulses penetrating to brain tissue and
depolarizing repetitively targeted neurons. According to pre-
vious data, magnetic pulses applied in high frequency (≥5
Hz) induce the long-term potentiation (LPT) with the
increase of neural activity and excitability in the stimulated
cortical area, whereas pulses in low frequency (≤1 Hz) sup-
press local neural activity by inducing the long-term depres-
sion [8]. A number of studies reported the beneficial effect of
rTMS for weakness, spasticity, and gait impairment in condi-
tions such as stroke, amyotrophic lateral sclerosis, multiple
sclerosis, parkinsonism, and spinal cord injury [8–14]. Until
now, this therapeutic option has not been investigated in any
form of HSP. According to previous reports, pure and com-
plicated forms, as well as AMN, are associated with decreased
activity and reduced excitability of the motor cortex [15–18].
Therefore, we hypothesized that bilateral, high-frequency
rTMS over primary motor areas for the muscles of lower
extremities will improve the walking, muscle strength, and
spasticity in patients with the mentioned types of HSP.
2. Methods
2.1. Participants. We recruited 15 patients (five women and
10 men; mean age 44 8 ± 10 1 years) with pure and compli-
cated forms of HSP and with AMN. All of them suffered from
chronic, slowly progressive spastic paraparesis with gait
impairment being clinically manifested and according to
patients’ complaints significantly impairing daily life. Diag-
nosis was confirmed by genetic testing or by family history
or was made by exclusion. Further inclusion criteria were
the ability to walk 10 meters without or with crutches
and age ≥ 18 years. Patients were excluded if they had
one or more contraindications to rTMS listed in the
safety guidelines issued by the International Federation
of Clinical Neurophysiology (IFCN), i.e., magnetic mate-
rial or electronic device in the body, history of epilepsy,
and pregnancy [19]. Further exclusion criteria were cog-
nitive impairment or psychiatric symptoms possibly inter-
fering with the study procedure.
2.2. Study Design. We conducted a randomized, controlled
trial in a crossover design. Investigations were made at the
Department of Neurology, Jagiellonian University Medical
College, Krakow, Poland. The study protocol was approved
by the Ethics Committee of the Jagiellonian University (Per-
mission No. 122.6120.119.2016). All participants gave their
written informed consent. The study has been conducted in
accordance with the Declaration of Helsinki.
2.3. Intervention. Before rTMS, every patient fulfilled a ques-
tionnaire for a TMS candidate based on the English original
published by the IFCN [20]. Stimulation was done with the
Magstim Rapid2 magnetic stimulator and with 110 mm dou-
ble cone coil. 10 Hz rTMS was delivered over the bilateral pri-
mary motor area (PMA) of the muscles of lower extremities.
The exact sites of stimulation and of estimating the motor
threshold (MT) were the “hot spots” for the left and right
abductor hallucis (AH). They were determined as the points
on the scalp where the magnetic stimuli had produced the
motor-evoked potentials (MEPs) of the highest amplitude.
The recording electrodes were placed over the AH and over
the proximal phalanx of the hallux. If no MEP could be
recorded from AH, then one of the more proximal muscles
of the lower extremity was chosen to determine the site of
stimulation and to estimate MT. If no MEPs were evocable,
rTMS was done with the coil placed over the vertex. Stimula-
tion intensity for rTMS was set at 90% of the resting motor
threshold (RMT) or, in case of prominent spasticity, when
patient could hardly maintain the full muscle relaxation,
90% of the active motor threshold (AMT). MT was deter-
mined using the relative frequency method described in
detail in the guidelines of the IFCN [21]. According to this
method, MT is defined as the lowest intensity of magnetic
field capable of evoking motor responses of certain amplitude
after at least five out of ten stimuli. The amplitude of response
required for estimation of RMT is ≥50 μV, and the muscle
should remain relaxed during examination. For AMT, the
amplitude should be ≥200 μV, and the muscle is slightly con-
tracted, which in this study was achieved by asking the
patient to perform a weak plantar flexion of the toes. In gen-
eral, the rTMS protocol resembled the one applied by Kakuda
et al. [22]. The real and sham stimulations contained five
stimulating sessions, one a day, performed during consecu-
tive working days. In every session, 1500 magnetic stimuli
were delivered over PMA of the muscles of each lower
extremity (3000 pulses per one session in total). The stimula-
tion was made with 10 Hz frequency and in trains lasting 7.5
seconds (every train contained 75 stimuli, and there were 40
trains, per hemisphere, per session). Trains were separated
with intervals lasting 56 seconds. During stimulation, partic-
ipants were in a semirecumbent position and wore ear plugs,
protecting them against the noise from the coil. The whole
procedure was the same for the sham stimulation except that
the coil was held perpendicularly to the scalp by rotating it
posteriorly, by 90 degrees. This maneuver reduces the mag-
netic field by 67–73% making it devoid of any biological
effects [23] but does not significantly change the clicking
noise and sensations, which are similar to those of the active
stimulation. In general, the sham procedure followed many
previous studies with rTMS, including those with stimulation
of motor areas of lower extremities [11, 22, 24]. Every
included participant underwent real and sham stimulations
in random order. The randomization list contained blocks
of random size of two or four. Information about assignment
of every patient was kept in sealed envelopes. Eight patients
received the active treatment first. rTMS took place in the
afternoon, usually between 2 p.m. and 4 p.m. The arms were
separated in every patient by an interval lasting between one
and three months. During participation in the study, patients
continued their usual physiotherapy and medication for
2 Neural Plasticity
spasticity in an unchanged way. Most patients who took bac-
lofen did it thrice a day with the second dose being taken
about 1 p.m., i.e., before the rTMS session.
2.4. Assessment of Cortical Excitability and of Conduction in
Central Motor Pathways. Before rTMS, the measurements
of MEP amplitude, of the central motor conduction time
(CMCT), and of the cortical silent period (CSP) were done.
In accordance with the IFCN guidelines [21], MEPs were
recorded five to six times during slight contraction of the
target muscle (usually AH) after stimuli of 140-170% of
RMT/AMT intensity. For the measurement, the MEP of the
highest amplitude was chosen. The MEP amplitude was
expressed in millivolts and as the percentage of the peripheral
response, i.e., of the compound muscle action potential
(CMAP) from the tibial nerve. CMCT was calculated using
the previously published formula [21], utilizing the minimal
F-wave latency. CMAP and F-wave were recorded according
to the standard method used in neurography [25]. CSP was
measured from five responses obtained during maximal
voluntary muscle contraction after magnetic stimuli of the
intensity of 140-170% of MT value, and the measurement
followed the guidelines of IFCN [21]. MEP was considered
abnormally low if its amplitude was less than 15% of CMAP
[21]. The normal values of CMCT were adopted from other
recommendations of IFCN [26].
2.5. Outcome Measurement. The primary endpoint was the
change in the 10-meter walk test (10MWT) after rTMS and
at follow-up. 10MWT measures the time a patient needs to
walk 10 meters on a flat floor. The usual aids for walking
should be used [27]. The alternative measure of gait perfor-
mance used as the secondary endpoint was the timed up
and go test (TUG). TUG is a complex measure of mobility.
The subject starts with standing up from the chair of 45 cm
height, walks three meters, turns around, walks back to the
chair, and sits down. The time needed to perform is assessed
[28]. Other secondary endpoints included the changes in the
strength and spasticity of lower extremities after rTMS. The
strength was measured with a microFET 2 hand-held dyna-
mometer (Hoggan Scientific LLC, Salt Lake, USA) and spas-
ticity with the Modified Ashworth Scale (MAS) [29]. Both
tests included the following movements bilaterally: hip
flexion, knee extension, knee flexion, ankle extension (dorsi-
flexion), and ankle flexion (plantar flexion). For every move-
ment’s strength tested in a given joint, the dynamometer was
placed at a point located few centimeters proximally to the
next distal joint (e.g., for testing the strength of the hip
flexion, it was the point a few centimeters above the knee,
and for the ankle extension, the point a few centimeters prox-
imally to the metatarsophalangeal joint). The subject was
instructed to execute the movement with his maximal
strength through three seconds. During this time, the exam-
iner resisted the examined subject’s force, keeping the dyna-
mometer in a constant position. To test the force of knee
extension, the patient was sitting upright and the dynamom-
eter was placed at the leg (above the ankle) hanging down,
i.e., the knee was flexed 90°. The force of knee flexion was
tested with the subject lying prone with the knee initially
flexed 30°. Other movements were tested in the supine
position. For every movement, the strength assessment was
repeated thrice, and the arithmetic mean was taken as the
final result. In case two consecutive measurements differed
more than 10 Newtons in a particular movement, a fourth
attempt was made, and the measurement which had shown
the greatest difference with the others was excluded from
consideration. MAS assess the spasticity in terms of resis-
tance to passive movement. It is a six-point scale where zero
indicates no spasticity and five indicates rigidity during pas-
sive movement, which is compatible with severe spasticity.
(In comparison to the version of MAS which uses a 1+ grade,
in our study, this grade meant grade 2, and grades 2, 3, and 4
meant in our study 3, 4, and 5, respectively.) All measure-
ments were performed before the first session of each
treatment arm, then directly (on the same day) after the last
session, and finally two weeks later as a follow-up. Partici-
pants and investigators performing the assessment but not
the person performing rTMS were blinded to the treatment
arm. Also, the person analysing the datasets was not blinded.
Outcome assessment was done in the afternoon, usually
between 2 and 4 p.m.
2.6. Statistical Analysis. The measurements of spasticity
and strength were averaged for both extremities in each
movement tested, and then, the scores for movements of
the proximal segments of lower extremities, i.e., hip flex-
ion, knee extension, and knee flexion, as well as of the dis-
tal segments, i.e., ankle flexion and extension, were
summarized. The times of performing 10MWT and
TUG, as well as the spasticity and the strength of proximal
and distal segments measured before active rTMS, were
compared with respective measurements done after active
rTMS and during follow-up. For sham rTMS, the same
comparisons were done. Owing to the small number of
subjects and the presence of ordinal data, the nonparamet-
ric Wilcoxon signed rank test was used. The significance
level was set to p < 0 05. Power analysis was conducted
in G∗Power v.3.2 software [30], for large (dz = 0 8),
medium (dz = 0 5), and small (dz = 0 2) effect sizes,
assuming a sample size of 15 subjects. The power for the
three effect sizes was 80%, 56%, and 18%, respectively.
The rest of calculations was done with the Statistica data
analysis software system, version 12.0 (StatSoft, 2008; Palo
Alto, CA, USA). Considering our interest in all symptoms
tested (gait performance, weakness, and spasticity), which
might respond to rTMS differently, as well as our inten-
tion to avoid excessive type II errors, which may occur
in such a limited number of subjects, we decided not to
conduct a correction for multiple comparisons.
3. Results and Discussion
One patient (male, 29 years of age) dropped out due to
seizure. The remaining 14 patients completed the study.
The seizure occurred during the third session of real stimula-
tion, after about 1000 stimuli over the right PMA were elic-
ited. It began with a tonic flexion of the hip and knee on
the left side lasting several seconds. Then, a loss of
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consciousness, generalized convulsions, and lateral tongue
bite followed. The seizure resolved spontaneously after two
to three minutes from its onset. There was a postictal phase
with confusion and drowsiness, which lasted 15 to 20
minutes. The patient was excluded from further stimulation.
An electroencephalography performed on the next day was
normal. Since then, the patient came several times to ambu-
latory control, and no sequelae occurred. Of other reported
side effects, one female participant (62 years of age) com-
plained about sleeplessness after the first two sessions of
active stimulation. Several other participants complained
about mild headaches during the first or the first and the sec-
ond sessions of active stimulation. In one participant with a
complicated form of HSP and atrophy of muscles of lower
extremities (male, 38 years of age), responses from AH were
below 50 μV despite maximal stimulation, so estimation of
MT was done with recordings from medial head of the gas-
trocnemius muscle (MHG). In another participant (male,
36 years of age), no response from any muscle was obtained,
and the intensity of therapeutic stimulation was set to 70% of
the maximal stimulator output. This patient did not present
muscular atrophy, and the lack of MEPs was most probably
due to affection of the corticospinal tract. In yet another par-
ticipant (male, 41 years of age), the interhemispheric differ-
ence in MT value was 14% of the maximal stimulator
output, so we decided to decrease the rTMS intensity over
the hemisphere with higher MT (right), equalizing it to the
rTMS intensity over the contralateral hemisphere. In three
patients (including the patient who dropped out), stimula-
tion intensity was derived from AMT (see Table 1). A techni-
cal complication, which occurred in several subjects who
were stimulated with intensity of 65% of the maximum stim-
ulator output or above, was the need to prolong the intervals
between the several last trains in the session due to coil over-
heating. This prolongation did not exceed two minutes. The
demographic and clinical data of recruited patients are pre-
sented in Table 1.
3.1. Assessment of Cortical Excitability and of Conduction in
Central Motor Pathways. All patients showed abnormalities.
The most common finding was the reduction of MEP ampli-
tude, followed by prolongation of CMCT, which was present
in all patients with AMN and in the majority of the others.
CSP showed relatively fewer abnormalities. Detailed data
are presented in Table 1.
3.2. Changes in Walking Speed, Muscle Strength, and
Spasticity.After real stimulation, the strength of the proximal
and distal muscles of lower extremities increased, and the
spasticity of the proximal muscles decreased. Changes in
spasticity were still present during follow-up assessment.
No effect of rTMS was seen in 10MWT and TUG. No
changes were seen after sham stimulation. Respective data
are presented in Table 2.
3.3. Relation of Therapeutic Effect to Motor Threshold.Due to
the big range of MT values in the studied group and resulting
big range of rTMS intensities as well as previous findings,
which linked changes in MT to HSP pathology [15], we
carried out a post hoc analysis of the relation of MT to the
therapeutic effect. The mean MT of 14 patients who com-
pleted the study was correlated with changes in strength
and spasticity induced by active rTMS, which were signifi-
cant, i.e., change in the strength of proximal and distal mus-
cles after rTMS and change in spasticity of proximal muscles
after rTMS and at follow-up. The MT value of the patient in
whom no MEPs could be evoked was adjusted to 100% (of
the maximal stimulator output). The change of strength in
both, proximal and distal muscles, showed an inverse corre-
lation with mean MT (R = −0 68, p = 0 008; R = −0 57, p =
0 034, respectively), whereas change in proximal spasticity
showed no significant correlation (R = 0 38, p = 0 184 for
change after rTMS; R = 0 03, p = 0 910 for change at follow-
up). The relation between change in muscle strength and
MT is presented in Figures 1 and 2.
3.4. Discussion. According to the authors’ best knowledge,
this is the first study which used rTMS for therapeutic pur-
poses in HSP. The data indicate that rTMS may have poten-
tial regarding the strength and spasticity of lower extremities
in this patient group. However, due to preliminary character,
this study needs repetition on a bigger sample and with more
sessions. Together with other studies using rTMS in acquired
gait disturbances [9–11], as well as weakness and spasticity
[8, 31], our work extends the evidence of the efficacy of non-
invasive brain stimulation in therapy of these deficits. The
key pathophysiological feature of the pure and complicated
forms of HSP as well as of AMN is the retrograde axonal
degeneration of the corticospinal tract [1, 32], which in the
present study has been reflected by reduction of the MEP
amplitude in almost all cases (in one case by a total absence
of MEP). Therefore, observed changes in strength and spas-
ticity may be associated with enhancement of excitability
and metabolic activity in PMA and remaining corticospinal
projections, which is a known effect of high-frequency rTMS
[8] and which in our study may act similarly in all three types
of paraparesis. At the cellular level, rTMS enhances BDNF-
TrkB complex signaling and upregulates NMDA receptors,
which induces synaptic plasticity, giving the possibility of
remodeling of the neural circuits within central motor path-
ways [33]. Such remodeling results in changes of the resting-
state functional connectivity as documented by functional
magnetic resonance imaging on healthy subjects [34] and
on patients with multiple sclerosis [35]. In both studies,
rTMS over PMA, applied in excitatory protocols, decreased
the connectivity between PMA and other brain areas, which
was paralleled by the increase of MEP amplitude [34] and
by reduction of spasticity in patients with multiple sclerosis
[35]. These findings led us to suppose that a decrease of
connectivity with other brain areas enhances the descending
output of the motor cortex and improves the function of the
pyramidal tract.
While the strength improved in both proximal and distal
muscles, the effect on spasticity was seen only in the former
ones. The lack of improvement in distal portions may be
explained by the deeper localization of the respective primary
motor areas, where the intensity of penetrating magnetic field
is reduced. The increase of muscle strength and the reduction
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of spasticity were not paralleled by improvement in walking
performance as measured by 10MWT and by TUG. The rea-
son for this may lie in the complexity of gait disturbances in
HSP, which not only results from weakness and spasticity but
also involves other mechanisms such as disturbed sequence
of the gait cycle due to abnormally high coactivation of
antagonistic muscles [36] or abnormalities in spinocerebellar
tracts [37]. In this light, it may be speculated that rTMS in
combination with specific gait training could allow patients
to implement the gains in strength and the decrease of
spasticity to improve walking. Such a synergistic effect has
been observed in patients after spinal cord injury who
received rTMS and robot-assisted gait training [38]. In
the present study, patients continued their usual physio-
therapy, which probably did not influence the results.
The second reason for lack of improvement in MWT
and TUG may be the small sample size with resulting
limited power of analysis. This is particularly true for
MWT, where the p value was close to 0.05 when compar-
ing measurements at the baseline and after rTMS.
Eight patients of our group received oral baclofen for
spasticity. According to previous studies, this drug increases
intracortical inhibition and reduces LTP-like plasticity in
the human motor cortex [39, 40]. It is possible that pharma-
cotherapy interfered with the effect of rTMS and reduced
observed improvement.
3.5. TMS Findings. Diagnostics with TMS showed abnormal-
ities in all patients with the reduction of MEP amplitude
being the most common finding. Similarly, the prolongation
of CMCT was present in all forms of spastic paraparesis,
including all patients with AMN. Of interest, one patient
with HSP showed very pronounced prolongation of CMCT.
This is in accordance with the study of Karle et al. [41]
who documented such a prolongation in a small subset
(6%) out of 128 patients with HSP and which may reflect
myelination abnormalities associated with some of the
genetic mutations leading to HSP. CSP showed similar
values across diagnoses, which with few exceptions were
normal and thus in line with the previous study done on
patients with HSP caused by mutation of SPG42 [42]. The
mean duration of CSP of our group was longer than values
reported for the HSP linked to SPG4 mutation [15] but
shorter than in patients with mutations in SPG4 and SPG7
Table 1: Demographic and clinical data and TMS findings of recruited patients.
N Gender
Age at
incl.
Diagnosis
Dis.
d.
Pharmacotherapy for spasticity MT left MT right CMCT
MEP
ampl.
CSP
1 M 38 AMN 13 Baclofen, tizanidine 74% 62% 22.4 ↑ 0.8/10% 107
2 M 56 AMN 3 68% 66% 18.4 ↑ 1.0/11% 280
3 M 41 AMN 14
Clonazepam, baclofen, and
Lorenzo’s oil
66% 78% 24.7 ↑ 0.5/4% 122
4 F 42 Unspecified pure 8 Tizanidine 72% 69% 19.3 ↑ 0.5/3% 119
5 M 38
Unspecified
compl.
20 67% MHG 66% MHG 33 ↑ 1.2/60%∗ 129
6 M 29 HSP3A 26 57% AMT 53% AMT 14.7 1.4/10% 189
7 M 36 HSP7 8 Baclofen
No
response
No
response
8 F 62
AMN gene
carrier
6 Baclofen 72% 65% 18 ↑ 2.4/13%
9 M 54 Unspecified pure 17 Baclofen 57% 54% 16.8 0.6/7% 111
10 M 50 Unspecified pure 8 54% 50% 14.3 1.5/17% 229
11 M 53 Unspecified pure 8 Baclofen 50% AMT 50% AMT 12.8 0.4/7% 121
12 M 41 Unspecified pure 19 54% AMT 40% AMT 16.2 1.1/7% 132
13 F 46
AMN gene
carrier
4 63% 67% 23.7 ↑ 0.7/10% 93
14 F 48
AMN gene
carrier
15 Baclofen 72% 72% 18.4 ↑ 1.0/7% 119
15 F 22
Unspecified
compl.
21 68% 76% 15 0.9/5% 109
F: female; M: male; age at incl.: age at inclusion; duration of sympt.: duration of symptoms (years); MT left: motor threshold of the left abductor hallucis (except
subject 5) in % of the maximal stimulator output; MT right: motor threshold of the right abductor hallucis (except subject 5) in % of the maximal stimulator
output; CMCT: central motor conduction time in milliseconds; MEP: motor-evoked potential (expressed in millivolts and as the percentage of the amplitude of
respective peripheral response); CSP: cortical silent period (in milliseconds); AMN: adrenomyeloneuropathy; HSP: hereditary spastic paraplegia; MHG: medial
head of gastrocnemius; compl.: complicated. ∗The unusually high amplitude of MEP in relation to peripheral response in this patient may be explained by
atrophy of MHG, which decreased the peripheral response more profoundly than MEP, because MEP amplitude was probably a summation of potentials
generated by MHG and adjacent muscles innervated by the peroneal nerve, which were located—due to atrophy—close to the recording electrode. Patient
no. 6 dropped out. CSP was not done in patient number 8. As the published normative data for MT were done using circular coil [24], we did not assess
MT regarding its normality.
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genes as reported by another study [43]. The stronger
magnetic stimuli used in our work in comparison to the for-
mer study and the measurement of CSP from the muscle of
the upper extremity (first dorsal interosseous) in the latter
may explain these discrepancies.
3.6. Relation of Therapeutic Effect to Motor Threshold. The
lower MT correlated in our group with the bigger effect of
real rTMS on muscle strength. Increased MT reflects among
other variables the lower number and density of corticocorti-
cal connections and corticospinal axons [21]. According to
this, we explain our finding by recognizing the low motor
threshold as a marker of an early disease stage with still
preserved plasticity and a high number of neural connec-
tions. Conversely, high motor threshold or complete lack of
motor responses reflects severe loss of central motor neurons
with only limited ability to respond to stimulation. Regarding
the small number of subjects, this finding needs however rep-
etition. Relation of motor threshold to the strength gain was
in our study not paralleled by similar relation to the reduc-
tion of spasticity, but here, the limited number of degrees of
freedom in the Ashworth scale may account for the lack of
significant correlation.
3.7. Adverse Event. Even though stimulation was performed
within the safety guidelines and even though our
Table 2: Results of gait, strength, and spasticity measurements.
(a)
Real stimulation
Before rTMS After rTMS p Follow-up p
10MWT 21 90 ± 32 14 16 48 ± 16 37 0.074 16 05 ± 15 80 0.124
TUG 20 68 ± 25 98 15 96 ± 13 55 0.221 17 76 ± 19 31 0.158
Ashworth prox. 4 96 ± 3 29 3 29 ± 2 31 0.001 3 54 ± 2 81 0.018
Ashworth dist. 3 75 ± 2 07 3 64 ± 1 76 0.813 3 82 ± 1 92 0.612
Strength prox. 464 28 ± 190 74 522 15 ± 217 00 0.004 497 50 ± 196 37 0.198
Strength dist. 316 83 ± 174 41 357 78 ± 175 73 0.041 327 20 ± 159 25 0.510
(b)
Sham stimulation
Before rTMS After rTMS p Follow-up p
10MWT 16 48 ± 14 49 18 18 ± 21 77 0.109 17 41 ± 19 83 0.300
TUG 17 83 ± 17 98 18 01 ± 20 39 0.433 18 60 ± 22 92 0.470
Ashworth prox. 3 68 ± 3 04 3 25 ± 2 52 0.508 3 14 ± 2 40 0.477
Ashworth dist. 3 39 ± 1 60 3 82 ± 2 03 0.236 3 36 ± 1 85 0.959
Strength prox. 467 02 ± 224 91 466 64 ± 187 19 0.975 452 70 ± 195 75 0.730
Strength dist. 272 39 ± 154 61 297 14 ± 154 41 0.158 294 84 ± 151 48 0.272
rTMS: repetitive transcranial magnetic stimulation; 10MWT: 10-meter walk test; TUG: timed up and go test; Ashworth prox.: spasticity score of proximal
muscles; Ashworth dist.: spasticity score of distal muscles; strength prox.: strength of proximal muscles; strength dist.: strength of distal muscles (in Newtons).
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Figure 1: Relation of the motor threshold to the change in the strength of proximal muscles after real rTMS. R = −0 68, p = 0 008.
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intervention was conducted similarly to previously pub-
lished trials with rTMS over PMA of lower extremities
[12, 14, 24, 44, 45], a seizure occurred. While conforming
to the guidelines does not eliminate the risk of seizure
completely, we suppose that the increased MT in HSP
[15] and the resulting relatively strong therapeutic mag-
netic field might increase such risk. Further, we expect
that estimating MT from the AH, as was performed in
our study, might be another predisposing factor. Despite
previous data showing that the AH has one of the lowest
MT among the muscles of the lower extremity [26], we
think that in some patients, MT for more proximal mus-
cles, e.g., quadriceps or iliopsoas, may be lower than that
for the AH due to a more superficial localization of the
respective motor cortex. This notion is somewhat sup-
ported by the present results, which showed better reac-
tivity to rTMS in proximal muscles. Therefore,
determining the intensity of repetitive stimulation on
the MT estimated in a single muscle might cause stimu-
lation of certain cortical areas with greater intensity than
desired. We suppose that estimation of MT from several
muscles, including proximal and distal ones, may increase
the safety of rTMS to lower extremities, especially in
patients with HSP, who require a strong magnetic field
for therapy. Another issue is the proximity of the motor
cortices for the left and right legs. In case of a significant
interhemispheric difference between MT values, the motor
cortex contralateral to the stimulated one could theoreti-
cally receive a supramaximal stimulation. According to
this, we consider that it may be beneficial for safety to
adapt the intensity of therapeutic stimulation to the MT
from the side where it is lower.
4. Limitations
The authors are aware of the preliminary character of the
study and of limited power of the results. The evaluation of
the datasets was done not blindly, which may be a potential
source of bias. Another issue is the limited number of ses-
sions, which might decrease the magnitude of the therapeutic
effect and may be the reason why the improvement in
strength was no more present in the follow-up. The cortical
excitability has not been assessed after rTMS, which may
limit the study value for optimization of rTMS protocols in
future trials. Finally, the abundant pharmacotherapy with
baclofen could considerably reduce observed effects.
5. Conclusions and Future Directions
Our study indicates that rTMS may have potential in
improving the strength and spasticity of lower extremities
in various forms of HSP. The proximal muscles of lower
extremities may respond better to therapy due to the superfi-
cial location of respective cortices. The results warrant future
studies, which should include therapy with more sessions
and more subjects as well as monitoring of cortical excitabil-
ity and neurophysiologic markers of spasticity. Further, the
effect of rTMS should be investigated in conjunction with
other therapies aiming at improvement of gait performance.
Finally, as the studies on rehabilitation of gait with rTMS
used different rTMS protocols, number of sessions, and coil
types [9–11], the comparative studies are needed to optimize
this kind of therapy. The seizure, which occurred, suggests
rTMS over PMA of lower extremities may require specific
precautions in patients with HSP.
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Figure 2: Relation of the motor threshold to the change in the strength of distal muscles after real rTMS. R = −0 57, p = 0 034.
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Data Availability
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to support the findings of this study are available from the
corresponding author upon request.
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